An assessment for the HSE of the weight-loss drug Wegovy has found that it is cost-effective and value for money, and should be made available to certain public patients, despite the high budget impact.
An assessment for the HSE of the weight-loss drug Wegovy has found that it is cost-effective and value for money, and should be made available to certain public patients, despite the high budget impact.
Leave a Reply